Evidence map›Paper›PMID 23434503›Full record

Trial reportSchizophrenia research2013

Effects of switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-year coronary heart disease risk and metabolic syndrome status: results from a randomized controlled trial.

T Scott Stroup, Matthew J Byerly, Henry A Nasrallah, Neepa Ray, Ahsan Y Khan, J Steven Lamberti, Ira D Glick, Richard M Steinbook, Joseph P McEvoy, Robert M Hamer

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Schizophrenia research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 3 pooled it
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 3 syntheses or guidelines pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 9 institutions in 2 countries.

T Scott StroupColumbia University College of Physicians and Surgeons, United States. stroups@nyspi.columbia.edu
Matthew J Byerly
Henry A Nasrallah
Neepa Ray
Ahsan Y Khan
J Steven Lamberti
Ira D Glick
Richard M Steinbook
Joseph P McEvoy
Robert M Hamer
University of North Carolina at Chapel Hill · USColumbia University · USDuke University Hospital · USSouthwestern University · USStanford University · USUniversity of Cincinnati · USUniversity of Miami · USUniversity of Oklahoma · USUniversity of Rochester · US

Funding

Zonisamide in Patients with Neuropathic Pain Associated with Diabetic NeuropathyM01RR000046 · NCRR · UNIV OF NORTH CAROLINA CHAPEL HILL · PI JOY, MELANIE S · 1985 to 2008
$38.5M
PUBLIC EDUCATION CAMPAIGN ON DEPRESSION DARTN01MH090001 · NIMH · UNIVERSITY OF NORTH CAROLINA CHAPEL HILL · 1989 to 2003
$10.4M
Pop-Track NIMHZ01MH900001 · NIMH · NATIONAL INSTITUTE OF MENTAL HEALTH · PI POP-TRACK, IC · 2002 to 2003
–
NCRR NIH HHS M01 RR000046NIMH NIH HHS N01 MH090001NIMH NIH HHS N01 MH900001
6 · The paper itself

Abstract

purposeThis study examined the clinical significance of switching from olanzapine, quetiapine, or risperidone to aripiprazole by examining changes in predicted risk of cardiovascular disease (CVD) according to the Framingham Risk Score (FRS) and metabolic syndrome status. FRS estimates 10-year risk of "hard" coronary heart disease (CHD) outcomes (myocardial infarction and coronary death) while metabolic syndrome is associated with increased risk of CVD, stroke, and diabetes mellitus.

methodChanges in FRS and metabolic syndrome status were compared between patients with BMI ≥ 27 and non-HDL-C ≥ 130 mg/dL randomly assigned to stay on stable current treatment (olanzapine, quetiapine, or risperidone) or switch to treatment with aripiprazole with 24 weeks of follow-up. All study participants were enrolled in a behavioral program that promoted healthy diet and exercise.

resultsThe pre-specified analyses included 89 switchers and 98 stayers who had post-baseline measurements needed to assess changes. Least squares mean estimates of 10-year CHD risk decreased more for the switch (from 7.0% to 5.2%) than the stay group (from 7.4% to 6.4%) (p = 0.0429). The odds ratio for having metabolic syndrome (stay vs. switch) at the last observation was 1.748 (95% CI 0.919, 3.324, p = 0.0885).

conclusionSwitching from olanzapine, quetiapine, or risperidone to aripiprazole was associated with larger reductions in predicted 10-year risk of CHD than the behavioral program alone. The advantage of switching on metabolic syndrome was not statistically significant. The benefits of switching must be balanced against its risks, which in this study included more discontinuations of the study treatment but no significant increase in symptoms or hospitalizations.

Indexed as

AdultAntipsychotic AgentsAripiprazoleBenzodiazepinesCoronary Artery DiseaseDibenzothiazepinesDrug SubstitutionFemaleHumansLongitudinal StudiesMaleMetabolic SyndromeMiddle AgedMulticenter Studies as TopicOdds RatioOlanzapineAntipsychotic AgentsAripiprazoleBenzodiazepinesDibenzothiazepinesOlanzapinePiperazinesQuetiapine FumarateQuinolonesRisperidone

Identifiers

PMID23434503
PMCPMC3622801
OpenAlexW2063649818

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.